All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
ALL HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma

Hot off the ASCO press: leukemia and transplant highlights

Jun 4, 2019

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, steering committee member, Gail Roboz from Weill Cornell Medicine, New York, US, shares highlights from the leukemia and transplant session. Dr. Roboz highlights that there is currently a lot going on within the AML sector, for example, the US has seen 8 new approvals in the last 2 years, and that there has been a lot of activity in newly diagnosed AML, relapsed AML, and also in novel targeted agents based on next-generation sequencing and profiling of patients, which ultimately is changing the way physicians think about treating all AML patients, both younger and older.

On the randomized trial front, Dr. Roboz emphasizes that investigators are eagerly awaiting the results of venetoclax added to azacitidine versus azacitidine alone, although this data is not presented at ASCO, the combination of venetoclax with hypomethylating agents has resulted in some impressive complete response numbers with the hope that this benefits overall survival as well. Dr. Roboz also shares thoughts on some practice changing abstracts, including gilteritinib data, as well as some phase II data on non- anticoagulant heparinoids called CX-01, from phase II data in older patients.

Hot off the ASCO press: leukemia and transplant highlights